Accuray Inc generated $401.947 million in full-year Revenue and recorded a $49.194 million net loss, compared with a $1.591 million loss previously. Investors face substantial indebtedness, including $182.0 million in term-loan borrowings, while one material weakness in internal control remained unresolved at June 30, 2026.

Key Highlights

  • Services revenue increased to $229.235 million, while product revenue was $172.712 million.
  • Accuray had $182.0 million outstanding under its term Loan at June 30, 2026.
  • One material weakness in internal control over financial reporting remained unremediated at June 30, 2026.

Accuray Inc (NASDAQ: ARAY) generated $401.947 million in full-year revenue and posted a $49.194 million net loss for the year ended June 30, 2026. Revenue was lower than the $458.505 million recorded in the previous year, while the loss widened from $1.591 million.

Services Revenue Reaches $229.235M

Services revenue rose to $229.235 million from $220.925 million, while product revenue declined to $172.712 million from $237.580 million. Total cost of revenue was $290.493 million, comprising $132.297 million for products and $158.196 million for services.

Gross profit was $111.454 million, down from $146.967 million. Research and Development expense was $37.753 million, selling and Marketing expense was $38.573 million, and general and administrative expense was $45.398 million. Restructuring expense was $16.172 million, compared with none in the previous year, bringing total operating expenses to $137.896 million.

Accuray recorded an operating loss of $26.442 million, compared with Operating Income of $7.839 million. Interest expense was $32.905 million, while income from an equity-method Investment was $1.124 million. Other income, net, was $5.011 million.

Borrowings Total $205.3M

Substantially all of Accuray’s Assets secure the Credit facilities. The company said a default could give lenders the right to foreclose on those assets, potentially severely impairing or eliminating its ability to continue operating.

Internal Control Weakness Remains

Accuray stated that one material weakness in internal control over financial reporting remained unresolved at June 30, 2026, after one previously identified weakness was remediated. The weaknesses related to reviewing footnote schedules supporting financial statement disclosures and assessing information needed for complete and accurate GAAP presentation and disclosure.

The weaknesses resulted in misstatements involving remaining performance obligations in the revenue footnote and led to restatements covering the year ended June 30, 2025, and several three-month periods. Accuray said ineffective controls could affect the production of timely and accurate financial results and could harm its Business and operating results.

Healthcare And Transaction Risks

The company identified healthcare regulatory and reimbursement risks, including exposure connected with the federal Stark Law and False Claims Act.

False Claims Act violations can require payment of three times the government’s actual damages, plus civil penalties ranging from $14,308 to $28,619 for each separate false claim. Accuray also identified risks tied to strategic transactions, including the ability to complete, integrate and execute those transactions.

Peers Moving on This News

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1138723/000143774926029098/aray20260630_10k.htm